Deals
I-Mab Seeks Multibillion-Dollar Cancer Drug Partnership
- Shanghai drugmaker in talks with pharmaceutical companies
- I-Mab agreed to $2.9 billion collaboration with AbbVie in 2020
This article is for subscribers only.
I-Mab is seeking a partner to jointly develop a cancer drug in the U.S. and Europe as the Chinese firm aims to replicate the success of last year’s $2.9 billion deal with AbbVie Inc., according to people familiar with the matter.
The Shanghai-based drug developer is working with advisers and is in talks with several global pharmaceutical companies over a potential deal for its Uliledlimab, or TJD5, treatment that could be worth a few billion dollars, the people said, asking not to be identified because the matter is private.